CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 30,489	$ 6,911
Marketable securities	2,053	1,973
Receivables	5,510	5,965
Inventories	1,192	1,195
Other assets, current	947	1,116
Total current assets	40,191	17,160
Property, plant and equipment	4,830	5,027
Goodwill	6,513	6,538
Other intangible assets	1,002	1,091
Deferred income taxes	1,624	1,371
Marketable securities	925	1,775
Other assets	2,348	2,024
Total Assets	57,433	34,986
Current Liabilities:
Short-term debt obligations	569	1,703
Accounts payable	1,888	1,892
Other liabilities, current	8,032	7,059
Total Current Liabilities	10,489	10,654
Accrued Income Taxes, Noncurrent	2,919	3,043
Other liabilities, noncurrent	1,881	1,516
Long-term debt	24,390	5,646
Total Liabilities	39,679	20,859
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock	0	0
Common stock	221	221
Capital in excess of par value of stock	2,206	2,081
Accumulated other comprehensive loss	(1,463)	(2,762)
Retained earnings	36,555	34,065
Less cost of treasury stock	(19,871)	(19,574)
Total Bristol-Myers Squibb Company Shareholders' Equity	17,648	14,031
Stockholders' Equity Attributable to Noncontrolling Interest	106	96
Total Equity	17,754	14,127
Total Liabilities and Equity	$ 57,433	$ 34,986